Mirae Asset Global Investments
URGN icon

Mirae Asset Global Investments’s UroGen Pharma URGN Stock Holding History

Mirae Asset Global Investments’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.2K Sell
2,179
-263
-11% -$7.13K ﹤0.01% 1286
2026
Q1 		$43.9K Buy
2,442
+167
+7% +$3.35K ﹤0.01% 1319
2025
Q4 		$53.3K Buy
2,275
+486
+27% +$10.5K ﹤0.01% 1382
2025
Q3 		$35.7K Buy
1,789
+8
+0.4% +$144 ﹤0.01% 1398
2025
Q2 		$24.4K Buy
1,781
+325
+22% +$3.12K ﹤0.01% 1369
2025
Q1 		$16.3K Buy
1,456
+50
+4% +$533 ﹤0.01% 1406
2024
Q4 		$15.1K Sell
1,406
-117
-8% -$1.4K ﹤0.01% 1459
2024
Q3 		$19.6K Buy
1,523
+444
+41% +$6.59K ﹤0.01% 1438
2024
Q2 		$18.3K Buy
+1,079
New +$15.3K ﹤0.01% 1392
2024
Q1 		– Sell
-11,348
Closed -$170K – 2651
2023
Q4 		$170K Buy
11,348
+60
+0.5% +$779 ﹤0.01% 2369
2023
Q3 		$158K Buy
11,288
+181
+2% +$2.9K ﹤0.01% 2361
2023
Q2 		$115K Buy
+11,107
New +$123K ﹤0.01% 2474
2021
Q3 		– Sell
-363
Closed -$6K – 1783
2021
Q2 		$6K Buy
+363
New +$6.56K ﹤0.01% 1690

Other funds holding URGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Mirae Asset Global Investments's URGN Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its UroGen Pharma (URGN) stake by 11% in Q2 2026, selling an estimated $7.13K and leaving 2,179 shares worth $80.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1286.

Mirae Asset Global Investments first reported a position in URGN in Q2 2021 and has held it in 13 quarters since. The position peaked at $170K in Q4 2023. 52 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Mirae Asset Global Investments held 2,179 shares of UroGen Pharma worth $80.2K as of Q2 2026.
  • Mirae Asset Global Investments sold 263 UroGen Pharma shares in Q2 2026, an estimated $7.13K.
  • UroGen Pharma made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1286 holding.
  • Mirae Asset Global Investments first reported a position in UroGen Pharma in Q2 2021 and has held it in 13 quarters since.
  • Mirae Asset Global Investments's UroGen Pharma position peaked at $170K in Q4 2023.
  • 52 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.